News

FDA approves alogliptin, alone and in combinations

Publish date: January 28, 2013

 

a.ault@elsevier.com

Twitter @aliciaault

Pages

Recommended Reading

Dalcetrapib Boosts HDL Without Benefiting Patients
MDedge Family Medicine
Ranbaxy Recalls Atorvastatin
MDedge Family Medicine
PCSK9 Antibodies Safely Cut LDL in Phase II
MDedge Family Medicine
Statins' Diabetogenic Impact Influenced by Underlying Risks
MDedge Family Medicine
Fatty Liver Disease: The Silent Epidemic
MDedge Family Medicine
Bariatric surgery cut vascular events in diabetes
MDedge Family Medicine
FDA panel backs approval of canagliflozin for type 2 diabetes
MDedge Family Medicine
How to prevent 1 million coronary events
MDedge Family Medicine
Metabolic syndrome skews Oncotype DX reliability
MDedge Family Medicine
HDL-raising: A good hypothesis gone bad
MDedge Family Medicine